DiaSorin gets FDA clearance for PCT assay
June 2018—DiaSorin received clearance from the FDA to market the Liaison Brahms PCT II Gen assay for the quantitative determination of procalcitonin.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace Directory
Cascade Pathology Services joins Aurora Diagnostics
June 2018—Aurora Diagnostics announced that Cascade Pathology Services, a physician-owned multispecialty pathology practice providing surgical pathology services to hospitals and physician groups in the Portland area, has joined Aurora Diagnostics.
Beckman introduces Access Sensitive Estradiol
June 2018—Beckman Coulter Diagnostics launched its Access Sensitive Estradiol in the U.S. and in the majority of worldwide markets. The assay aims to help laboratories deliver more accurate results for patients seeking answers to reproductive health questions.
SciGene FISH hybridizer
June 2018—SciGene introduced the CytoBrite Plus Slide Incubation System, a programmable FISH hybridizer with onboard temperature verification of each slide position, as required by CAP cytogenetics checklist item CYG.33950.
FDA-approved continuous glucose monitoring system
June 2018—Medtronic received FDA approval for its Guardian Connect continuous glucose monitoring system for people with diabetes ages 14 to 75 years.
BD launches ccfDNA blood collection tube in Europe
June 2018—Becton Dickinson announced the commercial availability of the CE-IVD-marked PAXgene Blood ccfDNA tube within the European Economic Area and Switzerland.
IgG subclass antibodies
June 2018—Binding Site’s Immunologicals Group announced the availability of affinity-purified, unconjugated, anti-human antibodies to the IgG subclasses, including IgG1, IgG2, IgG3, and IgG4, for IVD research use in solid phase enzyme immunoassay based test methods, especially ELISAs, and other potential testing applications.
Genoptix completes Rosetta acquisition
June 2018—Rosetta Genomics’ stockholders have approved the acquisition of the company by Genoptix, which will immediately begin marketing, selling, and distributing Rosetta Genomics’ products.
POC immunoassay testing system
June 2018—Sekisui Diagnostics has partnered with Qualigen to distribute the FastPack IP System, Qualigen’s POC immunoassay testing system.
AdvantEdge acquires PMI, 5/18
May 2018—AdvantEdge Healthcare Solutions, a medical billing company, has acquired Professional Management, Inc., a Baltimore-based medical billing company that provides billing services to pathology, radiology, and emergency medicine physician groups.